The spread of the Delta variant has put countries around the world on high alert.Dr. Roy M. Gulick, chief of the Division of Infectious Diseases at NewYork-Presbyterian/Weill Cornell Medical Center and professor of medicine at Weill Cornell Medicine, answers questions about the new threat.
A team led by researchers at Weill Cornell Medicine and Children’s National Hospital has developed a unique pre-clinical model that enables the study of long-term HIV infection, and the testing of new therapies aimed at curing the disease.
Using an antibody to block HIV from infecting cells may be an effective and more convenient way to prevent acquisition of HIV, suggests a preliminary study by a multi-institution team of researchers led by investigators from Weill Cornell Medicine and Oregon Health and Science University (OHSU).
Soon after the first case of COVID-19 was reported in New York City last March, a group of about 10 physician-scientists at Weill Cornell Medicine met to discuss a pressing issue: there were no known treatments for severe cases of the disease.
When COVID-19 first appeared in NYC hospitals, Weill Cornell Medicine and NewYork-Presbyterian physicians and scientists documented early observations of clinical and pathological characteristics in two publications.
With the goal of advancing the fight against COVID-19, the Partners of Citadel and Citadel Securities have made a $2 million gift to Weill Cornell Medicine to develop new approaches to protect people from the disease and identify new cases of it.
Dr. Kyu Rhee, an associate professor of medicine in the Division of Infectious Diseases at Weill Cornell Medicine, has been awarded a Physician-Scientist Institutional Award by the Burroughs Wellcome Fund.
Physicians, researchers and policymakers around the globe are grappling with the rise of antibiotic-resistant bacteria—a threat with the potential to derail decades of medical advances.
